Overview

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma

Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with resectable local advanced oral squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital of Stomatology, Wuhan University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Cisplatin
Docetaxel
Fluorouracil